Studies of the biogenic amine transporters. V. Demonstration of two binding sites for the cocaine analog [125I]RTI-55 associated with the 5-HT transporter in rat brain membranes. 1995

M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, Maryland, USA.

Earlier work characterized the binding of the high-affinity cocaine analog 3 beta-(4-125iodophenyl)-tropane-2-carboxylic acid methyl ester ([125I]RTI-55) to membranes prepared from rat caudate. That investigation demonstrated that [125I]RTI-55-labeled serotonin (5-HT) transporters in addition to dopamine (DA) transporters and resolved [125I]RTI-55 binding to 5-HT transporters into two distinct components. In the present study, we characterized [125I]RTI-55 binding to membranes prepared from whole rat brain minus caudate. The first series of experiments established that [125I]RTI-55 labels both DA and 5-HT transporters and that 50 nM paroxetine and either 1000 nM 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)homopiperazine (LR1111) or 500 nM (RTI-120) could be used to block [125I]RTI-55 binding to the 5-HT and DA transporters, thereby generating selective assay conditions for the DA and 5-HT transporters, respectively. Selective lesioning of dopaminergic and serotonergic neurons with intracerebroventricular 6-hydroxydopamine and 5,7-dihydroxytryptamine selectively decreased [125I]RTI-55 binding to DA and 5-HT transporters, respectively, thereby confirming the selectivity of the assay conditions. The ligand-selectivity pattern of the whole brain minus caudate 5-HT transporter correlated significantly with that of the caudate 5-HT transporter, although there were some striking differences for selected test agents. Additional experiments resolved [125I]RTI-55 binding to the 5-HT transporter into two components. A ligand-selectivity analysis of the two components failed to identify a highly selective test agent. In summary, the major findings of the present study are that [125I]RTI-55 labels both DA and 5-HT transporters in membranes prepared from whole brain minus caudate, that 50 nM paroxetine and either 1000 nM LR1111 or 500 nM RTI-120 can be used as a blocking agent to generate selective assay conditions for the DA and 5-HT transporters, respectively, and that [125I]RTI-55 binding to the 5-HT transporter can be resolved into two similar components.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines

Related Publications

M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
July 1994, The Journal of pharmacology and experimental therapeutics,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
July 1995, The Journal of pharmacology and experimental therapeutics,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
December 1998, The American journal of physiology,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
April 1998, Progress in neuro-psychopharmacology & biological psychiatry,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
June 1996, The Journal of pharmacology and experimental therapeutics,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
March 1994, The Journal of pharmacology and experimental therapeutics,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
December 1993, Journal of neurochemistry,
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
September 1992, Synapse (New York, N.Y.),
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
December 1995, Synapse (New York, N.Y.),
M L Silverthorn, and C M Dersch, and M H Baumann, and J L Cadet, and J S Partilla, and K C Rice, and F I Carroll, and K M Becketts, and A Brockington, and R B Rothman
July 1994, Journal of chemical neuroanatomy,
Copied contents to your clipboard!